公开(公告)号：US20100267667A1

公开(公告)日：2010-10-21

申请号：US12602956

申请日：2008-06-04

Applicant: Aviv Gazit ,  Shimon Slavin ,  Esther Priel ,  Sara Yitzchak

Inventor： Aviv Gazit ,  Shimon Slavin ,  Esther Priel ,  Sara Yitzchak

IPC: A61K31/695 ,  A61K31/497 ,  A61K31/4545 ,  A61K31/4025 ,  A61K31/5377 ,  A61K31/085 ,  A61K31/05 ,  A61K31/66 ,  A61K31/555 ,  A61P17/00 ,  A61P3/10 ,  A61P35/00 ,  A61P37/00 ,  A61P9/00

CPC classification number: C07C215/80 ,  A61K31/03 ,  A61K31/05 ,  A61K31/055 ,  A61K31/136 ,  A61K31/66 ,  A61K31/695 ,  C07C39/367 ,  C07C43/225 ,  C07C43/23 ,  C07C215/50 ,  C07D213/16 ,  C07D213/30 ,  C07D295/096 ,  C07D295/135 ,  C07F9/5022

Abstract: The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.

Abstract translation: 本发明涉及一系列化合物和包含其的组合物用于活化端粒酶和治疗与之相关的疾病，病症和/或病症的用途。

公开(公告)号：US20100189750A1

公开(公告)日：2010-07-29

申请号：US12677543

申请日：2008-09-11

Applicant: Ilan Volovitz ,  Lea Eisenbach ,  Irun R. Cohen ,  Zvi Ram ,  Shimon Slavin

Inventor： Ilan Volovitz ,  Lea Eisenbach ,  Irun R. Cohen ,  Zvi Ram ,  Shimon Slavin

IPC: A61K39/00 ,  A61P35/00

CPC classification number: A61K39/0011 ,  A61K2039/5152

Abstract: A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.

Abstract translation: 提供了在有需要的受试者的免疫特异部位中治疗癌症的方法。 该方法包括系统地施用受试者的免疫特权部位之外的区域，治疗有效量的受试者肿瘤的天真，活的细胞，肿瘤位于免疫特异位点以产生免疫应答 从而治疗受试者的免疫特异部位的癌症。

公开(公告)号：US06143292A

公开(公告)日：2000-11-07

申请号：US930071

申请日：1997-11-21

Applicant: Shimon Slavin

Inventor： Shimon Slavin

IPC: A61J1/10 ,  A61K31/00 ,  A61K35/14 ,  A61K35/17 ,  A61K38/00 ,  A61K38/20 ,  A61K38/21 ,  A61K39/395 ,  A61K45/00 ,  A61P35/00 ,  A61P35/02 ,  C12N5/08 ,  A61K35/28

CPC classification number: A61K38/2013 ,  A61K35/17

Abstract: A method of treating a human cancer patient having a solid tumor comprising malignant cells is disclosed, wherein the patient having undergone a cancer therapy regimen comprising allogeneic stem cell transplantation. The method comprises administering allogeneic lymphocytes to the patient and monitoring the patient for levels of malignant cells.

Abstract translation: PCT No.PCT / US96 / 07652 Sec。 371日期：1997年11月21日 102（e）1997年11月21日PCT PCT 1996年5月24日PCT公布。 WO96 / 37208 PCT公开号 日本1996年11月28日公开了一种治疗患有包含恶性细胞的实体肿瘤的人类癌症患者的方法，其中已经经过包括同种异体干细胞移植的癌症治疗方案的患者。 该方法包括向患者施用同种异体淋巴细胞并监测患者恶性细胞的水平。

公开(公告)号：US5891879A

公开(公告)日：1999-04-06

申请号：US722046

申请日：1996-12-09

Applicant: Arnon Nagler ,  Shimon Slavin ,  Israel Vlodavsky ,  Mark Pines

Inventor： Arnon Nagler ,  Shimon Slavin ,  Israel Vlodavsky ,  Mark Pines

IPC: A61K31/517 ,  A61K31/505

CPC classification number: A61K31/517

Abstract: The invention provides a pharmaceutical composition for preventing restens by the inhibition of vascular smooth muscle cell proliferation, comprising a compound of formula I: ##STR1## wherein: n=1 or 2 R.sub.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;R.sub.2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, andR.sub.3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonylas active ingredient therein, and the physiologically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier.

Abstract translation: PCT No.PCT / US95 / 11186 Sec。 371日期1996年12月9日第 102（e）日期1996年12月9日PCT提交1995年8月29日PCT公布。 出版物WO96 / 06616 日期：1996年3月7日本发明提供了一种用于通过抑制血管平滑肌细胞增殖来预防再狭窄的药物组合物，其包含式I化合物：其中：n = 1或2 R 1为下列成员： 的氢，卤素，硝基，苯并，低级烷基，苯基和低级烷氧基; R2是由羟基，乙酰氧基和低级烷氧基组成的组的成员，R3是作为其中作为活性成分的氢和低级链烯氧基 - 羰基的成员，其生理上可接受的盐与药学上可接受的盐组合 可接受的载体

公开(公告)号：US5594005A

公开(公告)日：1997-01-14

申请号：US313302

申请日：1994-12-23

Applicant: Shimon Slavin ,  Lola Weiss ,  David Gross

Inventor： Shimon Slavin ,  Lola Weiss ,  David Gross

IPC: A61K31/47 ,  A61P3/08 ,  A61P3/10 ,  C07D215/54 ,  C07D215/56

CPC classification number: C07D215/54 ,  A61K31/47 ,  C07D215/56 ,  Y10S514/866 ,  Y10S514/884

Abstract: Quinoline-3-carboxamide compounds of formula (I) are effective in preventing, treating or ameliorating Type I diabetes. ##STR1## wherein ----- represents two conjugated double bonds between the atoms comprised by the dashed line, X.sub.1 and X.sub.2 are independently selected from an oxygen atom or NH.sup.9, H.sup.1-9 independently represent a hydrogen atom or a substituent, wherein H.sup.7 and H.sup.8 are attached to different atoms selected from X.sub.1, X.sub.2 and the ring nitrogen atom of the quinoline ring. In particular, X.sub.1 and X.sub.2 being bound by a single bond to the ring when H.sup.7 or H.sup.8 is bonded thereto and by a double bond when H.sup.7 or H.sup.8 is not bonded thereto.

Abstract translation: PCT No.PCT / SE93 / 00272 Sec。 371日期1994年12月23日第 102（e）日期1994年12月23日PCT 1993年3月31日PCT公布。 WO93 / 19756 PCT公开号 日期：1993年10月14日式（I）的喹啉-3-甲酰胺化合物可有效预防，治疗或改善I型糖尿病。 其中-----表示由虚线包含的原子之间的两个共轭双键，X1和X2独立地选自氧原子或NH9，H1-9独立地表示氢原子或取代基，其中H7 和H8连接到选自X1，X2和喹啉环的环氮原子的不同原子。 特别地，当H 7或H 8键合时，X 1和X 2通过单键与环结合，当H7或H8未键合时，X 1和X 2与双键结合。

公开(公告)号：US10421961B2

公开(公告)日：2019-09-24

申请号：US13377558

申请日：2010-06-10

Applicant: Chaya Brodie ,  Shimon Slavin

Inventor： Chaya Brodie ,  Shimon Slavin

IPC: C12N15/113 ,  C12N5/0793 ,  A61K31/7105

Abstract: Some embodiments of the invention comprise methods, systems, and compositions to selectively induce, whether in vitro or in vivo, the neuronal differentiation of multipotent stromal cells through the application of microRNAs, including but not limited to miRNA-124, miRNA-137 and/or miRNA-9* expression products of those miRNAs, and molecules and compositions containing functional elements of those miRNAs. Some embodiments of the invention also comprise the therapeutic administration and use of such induced cells to treat mammalian injuries and diseases, including but not limited to, nervous system injuries or diseases that may otherwise result in decreased cell or system function.

公开(公告)号：US20130149288A1

公开(公告)日：2013-06-13

申请号：US13817535

申请日：2011-08-14

Applicant: Shimon Slavin ,  Chaya Brodie

Inventor： Shimon Slavin ,  Chaya Brodie

IPC: C12N5/079

CPC classification number: C12N5/0622 ,  A61K35/12 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/30 ,  C12N2330/10 ,  C12N2500/25 ,  C12N2501/39 ,  C12N2501/65 ,  C12N2506/025 ,  C12N2506/1353 ,  C12N2506/1384 ,  C12N2506/1392

Abstract: A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating the population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.

Abstract translation: 公开了一种产生可用于治疗受试者脑部疾病的细胞群的方法。 所述方法包括使间充质干细胞（MSC）与至少一种外源miRNA接触，所述外源miRNA具有与选自SEQ ID NO：15-19和27-35的序列至少90％相同的核酸序列，从而产生 细胞群和/或产生神经营养因子，其可以向受损组织或局部驻留的干细胞提供重要信号。 通过miR分化的MSC也可以分泌miR并将其递送至相邻细胞，并因此向相邻内源性正常或恶性细胞提供重要信号。

公开(公告)号：US20100311841A1

公开(公告)日：2010-12-09

申请号：US12742036

申请日：2008-11-06

Applicant: Arie Dagan ,  Shimon Gatt ,  Shimon Slavin

Inventor： Arie Dagan ,  Shimon Gatt ,  Shimon Slavin

IPC: A61K31/135 ,  C07C213/00

CPC classification number: C07C323/32 ,  C07C381/12

Abstract: Therapeutic compounds based on synthetic sphingolipid analogs are provided, particularly alkylthiophenyl substituted ceramide analogs, suitable for treating degenerative, infectious, and other diseases.

Abstract translation: 提供了基于合成鞘脂类似物的治疗化合物，特别是烷基硫代苯基取代的神经酰胺类似物，其适于治疗退行性，感染性和其它疾病。

公开(公告)号：US07347999B2

公开(公告)日：2008-03-25

申请号：US10471048

申请日：2002-03-05

Applicant: Shimon Slavin ,  Olga Gurevitch ,  Basan Gowda S. Kurkalli ,  Tatyana Prigozhina

Inventor： Shimon Slavin ,  Olga Gurevitch ,  Basan Gowda S. Kurkalli ,  Tatyana Prigozhina

IPC: A61K35/32 ,  A61K35/28

CPC classification number: A61K35/32 ,  A61K35/28 ,  A61K38/1875 ,  A61K2300/00

Abstract: A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM), optionally comprising bone morphogenetic protein (BMP), particularly for use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, and methods of transplantation/implantation thereof. The composition and methods of the invention enable restoring and/or enhancing the formation of hematopoiectic microenvironment originating from the transplanted BMC, and are useful in the treatment of hematopoietic disorders, such as deficiency of stem cells and/or their products, genetic conditions resulting in abnormal stem cells and/or products, or hematopoietic disorders of malignant or non-malignant origin. The composition and method of the invention may also be used for the induction of graft tolerence, for the prevention of graft-v-host disease. It is mostly important that the compositions and methods of the invention may be applied for the treatment of diseases affecting primarily or secondarily the stromal microenvironment that supports and regulates hematopoiesis. Further provided is a kit for transplantation into a mammal of BMC in admixture with DBM and/or MBM.

Abstract translation: 包含骨髓细胞（BMC）和去矿物质骨基质（DBM）和/或矿化骨基质（MBM）的组合物，任选地包括骨形态发生蛋白（BMP），特别是用于骨髓移植，进入骨髓腔或骨骼外 位点及其移植/植入方法。 本发明的组合物和方法能够恢复和/或增强源自移植的BMC的造血微环境的形成，并且可用于治疗造血障碍，例如干细胞和/或其产物的缺乏，导致 异常干细胞和/或产物，或恶性或非恶性起源的造血障碍。 本发明的组合物和方法也可用于诱导移植物穿刺，用于预防移植物抗宿主病。 最重要的是，本发明的组合物和方法可以用于治疗主要或二次影响支持和调节造血的基质微环境的疾病。 还提供了用于与DBM和/或MBM混合的用于移植到BMC的哺乳动物中的试剂盒。

公开(公告)号：US20070099987A1

公开(公告)日：2007-05-03

申请号：US10589623

申请日：2005-02-16

Applicant: Lola Weiss ,  Michael Zeira ,  Raphael Mechoulam ,  Shimon Slavin ,  Ruth Gallily

Inventor： Lola Weiss ,  Michael Zeira ,  Raphael Mechoulam ,  Shimon Slavin ,  Ruth Gallily

IPC: A61K31/353 ,  A61K31/192 ,  A61K31/05

CPC classification number: A61K31/05 ,  A61K36/185

Abstract: Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.

Abstract translation: 使用大麻二醇来制造用于治疗或预防糖尿病和/或胰岛炎的药物。